Norris Perne & French LLP MI boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.5% during the second quarter, Holdings Channel reports. The fund owned 98,305 shares of the medical research company’s stock after buying an additional 5,120 shares during the period. Charles River Laboratories International comprises 1.7% of Norris Perne & French LLP MI’s holdings, making the stock its 13th largest position. Norris Perne & French LLP MI’s holdings in Charles River Laboratories International were worth $9,944,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Pembroke Management LTD raised its position in Charles River Laboratories International by 6.2% in the first quarter. Pembroke Management LTD now owns 271,735 shares of the medical research company’s stock worth $24,442,000 after buying an additional 15,900 shares during the last quarter. Canada Pension Plan Investment Board raised its position in Charles River Laboratories International by 75.3% in the first quarter. Canada Pension Plan Investment Board now owns 12,800 shares of the medical research company’s stock worth $1,151,000 after buying an additional 5,500 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in Charles River Laboratories International by 1.2% in the first quarter. Oregon Public Employees Retirement Fund now owns 16,446 shares of the medical research company’s stock worth $1,479,000 after buying an additional 200 shares during the last quarter. Wesbanco Bank Inc. raised its position in Charles River Laboratories International by 81.8% in the first quarter. Wesbanco Bank Inc. now owns 5,849 shares of the medical research company’s stock worth $526,000 after buying an additional 2,632 shares during the last quarter. Finally, Cardinal Capital Management raised its position in Charles River Laboratories International by 1.1% in the first quarter. Cardinal Capital Management now owns 7,035 shares of the medical research company’s stock worth $633,000 after buying an additional 76 shares during the last quarter. 95.81% of the stock is currently owned by institutional investors.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 99.53 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $102.32. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 29.13 and a beta of 1.02. The firm has a 50-day moving average of $99.43 and a 200 day moving average of $90.83.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.15. The firm had revenue of $445.80 million for the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The business’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.98 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a share repurchase plan on Wednesday, May 10th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “Charles River Laboratories International, Inc. (NYSE:CRL) Position Boosted by Norris Perne & French LLP MI” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/07/charles-river-laboratories-international-inc-nysecrl-position-boosted-by-norris-perne-french-llp-mi.html.

A number of research firms recently weighed in on CRL. Jefferies Group LLC reissued a “buy” rating and set a $121.00 price target on shares of Charles River Laboratories International in a research report on Friday, June 30th. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Citigroup Inc. reissued a “neutral” rating and set a $104.00 price target (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th. Barclays PLC reissued a “hold” rating and set a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Finally, BidaskClub lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $97.06.

In other news, Chairman James C. Foster sold 43,154 shares of the firm’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the sale, the chairman now owns 361,178 shares of the company’s stock, valued at approximately $36,117,800. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Ross Smith sold 945 shares of the firm’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $95.00, for a total transaction of $89,775.00. Following the sale, the insider now directly owns 14,203 shares in the company, valued at approximately $1,349,285. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 80,499 shares of company stock worth $7,946,191. Insiders own 2.20% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.